The drug is currently being evaluated in two fully recruited global Phase 3 studies for progressive and tophaceous gout, with results expected in 2026.
The study also showed a clear dose-dependent trend, with the 75 mg QD group outperforming the 50 mg QD cohort
This is the first approval of a prescription transdermal dosage Form in the European markets from this facility
The launch of the study was on the occasion of the International Day of Persons with Disabilities
AEF0217 is a first-in-class CB1 receptor signaling-specific inhibitor
The acquisitions merge DatCard and Sorna’s expertise in clinical data sharing with Avandra’s de-identified patient data aggregation platform
Suffering from acute migraine? You may soon bid adieu to the debilitating headache
Despite steep funding setbacks, the global HIV response has gained momentum in 2025 with the introduction of twice-yearly injectable LEN
Subscribe To Our Newsletter & Stay Updated
